Vaccins contre les hépatites virales : Questions médicales fréquentes
Nom anglais: Viral Hepatitis Vaccines
Descriptor UI:D014761
Tree Number:D20.215.894.899.955
Termes MeSH sélectionnés :
Time-to-Pregnancy
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Vaccins contre les hépatites virales : Questions médicales les plus fréquentes",
"headline": "Vaccins contre les hépatites virales : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Vaccins contre les hépatites virales : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-21",
"dateModified": "2025-02-15",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Vaccins contre les hépatites virales"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Vaccins antiviraux",
"url": "https://questionsmedicales.fr/mesh/D014765",
"about": {
"@type": "MedicalCondition",
"name": "Vaccins antiviraux",
"code": {
"@type": "MedicalCode",
"code": "D014765",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D20.215.894.899"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Vaccins anti-hépatite A",
"alternateName": "Hepatitis A Vaccines",
"url": "https://questionsmedicales.fr/mesh/D022362",
"about": {
"@type": "MedicalCondition",
"name": "Vaccins anti-hépatite A",
"code": {
"@type": "MedicalCode",
"code": "D022362",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D20.215.894.899.955.395"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Vaccins anti-hépatite B",
"alternateName": "Hepatitis B Vaccines",
"url": "https://questionsmedicales.fr/mesh/D017325",
"about": {
"@type": "MedicalCondition",
"name": "Vaccins anti-hépatite B",
"code": {
"@type": "MedicalCode",
"code": "D017325",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D20.215.894.899.955.400"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Vaccins contre les hépatites virales",
"alternateName": "Viral Hepatitis Vaccines",
"code": {
"@type": "MedicalCode",
"code": "D014761",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Christoph Neumann-Haefelin",
"url": "https://questionsmedicales.fr/author/Christoph%20Neumann-Haefelin",
"affiliation": {
"@type": "Organization",
"name": "Klinik für Innere Medizin II - Gastroenterologie, Hepatologie, Endokrinologie, Infektiologie, Universitätsklinikum Freiburg, Freiburg, Deutschland."
}
},
{
"@type": "Person",
"name": "Robert Thimme",
"url": "https://questionsmedicales.fr/author/Robert%20Thimme",
"affiliation": {
"@type": "Organization",
"name": "Klinik für Innere Medizin II - Gastroenterologie, Hepatologie, Endokrinologie, Infektiologie, Universitätsklinikum Freiburg, Freiburg, Deutschland. robert.thimme@uniklinik-freiburg.de."
}
},
{
"@type": "Person",
"name": "Maria Buti",
"url": "https://questionsmedicales.fr/author/Maria%20Buti",
"affiliation": {
"@type": "Organization",
"name": "Liver Unit, Hospital Universitario Valle Hebron and Civerehd del Instituto Carlos III, Barcelona, Spain."
}
},
{
"@type": "Person",
"name": "Stefan Zeuzem",
"url": "https://questionsmedicales.fr/author/Stefan%20Zeuzem",
"affiliation": {
"@type": "Organization",
"name": "Department of Internal Medicine 1, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany."
}
},
{
"@type": "Person",
"name": "Fabien Zoulim",
"url": "https://questionsmedicales.fr/author/Fabien%20Zoulim",
"affiliation": {
"@type": "Organization",
"name": "INSERM U1052, CNRS UMR-5286, Cancer Research Center of Lyon, Lyon, France."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Maternal exposure to metals and time-to-pregnancy: The MIREC cohort study.",
"datePublished": "2024-01-18",
"url": "https://questionsmedicales.fr/article/38239019",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/1471-0528.17759"
}
},
{
"@type": "ScholarlyArticle",
"name": "Pregnancy in the time of COVID-19: towards Fetal monitoring 4.0.",
"datePublished": "2023-01-16",
"url": "https://questionsmedicales.fr/article/36647041",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12884-023-05349-3"
}
},
{
"@type": "ScholarlyArticle",
"name": "Predicting Preeclampsia Pregnancy Termination Time Using sFlt-1.",
"datePublished": "2022-06-20",
"url": "https://questionsmedicales.fr/article/35795634",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fmed.2022.900639"
}
},
{
"@type": "ScholarlyArticle",
"name": "[Seroprevalence of Hepatitis B virus in pregnancy women at the time of delivery].",
"datePublished": "2024-03-13",
"url": "https://questionsmedicales.fr/article/38801363",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.32641/andespediatr.v95i2.4790"
}
},
{
"@type": "ScholarlyArticle",
"name": "Association between job control and time to pregnancy in a preconception cohort.",
"datePublished": "2023-11-28",
"url": "https://questionsmedicales.fr/article/38036244",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.fertnstert.2023.11.022"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Mélanges complexes",
"item": "https://questionsmedicales.fr/mesh/D045424"
},
{
"@type": "ListItem",
"position": 3,
"name": "Produits biologiques",
"item": "https://questionsmedicales.fr/mesh/D001688"
},
{
"@type": "ListItem",
"position": 4,
"name": "Vaccins",
"item": "https://questionsmedicales.fr/mesh/D014612"
},
{
"@type": "ListItem",
"position": 5,
"name": "Vaccins antiviraux",
"item": "https://questionsmedicales.fr/mesh/D014765"
},
{
"@type": "ListItem",
"position": 6,
"name": "Vaccins contre les hépatites virales",
"item": "https://questionsmedicales.fr/mesh/D014761"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Vaccins contre les hépatites virales - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Vaccins contre les hépatites virales",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-06",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Vaccins contre les hépatites virales",
"description": "Quels sont les symptômes de l'hépatite A ?\nL'hépatite B peut-elle être asymptomatique ?\nComment se manifeste l'hépatite C ?\nQuels signes indiquent une hépatite aiguë ?\nL'hépatite virale peut-elle causer des complications ?",
"url": "https://questionsmedicales.fr/mesh/D014761?mesh_terms=Time-to-Pregnancy&page=4#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Vaccins contre les hépatites virales",
"description": "Comment les vaccins contre l'hépatite A sont-ils administrés ?\nQui devrait recevoir le vaccin contre l'hépatite B ?\nLes vaccins contre l'hépatite A sont-ils efficaces ?\nÀ quel âge doit-on vacciner les enfants contre l'hépatite B ?\nLes voyageurs doivent-ils se faire vacciner contre l'hépatite A ?",
"url": "https://questionsmedicales.fr/mesh/D014761?mesh_terms=Time-to-Pregnancy&page=4#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Vaccins contre les hépatites virales",
"description": "Quel est le traitement de l'hépatite A ?\nComment traite-t-on l'hépatite B chronique ?\nL'hépatite C est-elle curable ?\nQuels médicaments sont utilisés pour l'hépatite B ?\nY a-t-il un vaccin pour l'hépatite C ?",
"url": "https://questionsmedicales.fr/mesh/D014761?mesh_terms=Time-to-Pregnancy&page=4#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Vaccins contre les hépatites virales",
"description": "Quelles sont les complications de l'hépatite B ?\nL'hépatite A peut-elle causer des complications ?\nQuels risques sont associés à l'hépatite C ?\nComment prévenir les complications de l'hépatite ?\nLes complications de l'hépatite peuvent-elles être réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D014761?mesh_terms=Time-to-Pregnancy&page=4#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Vaccins contre les hépatites virales",
"description": "Quels sont les facteurs de risque pour l'hépatite A ?\nQui est à risque d'hépatite B ?\nL'hépatite C est-elle transmissible par le sang ?\nLes travailleurs de la santé sont-ils à risque d'hépatite ?\nLes personnes atteintes de maladies chroniques sont-elles plus à risque ?",
"url": "https://questionsmedicales.fr/mesh/D014761?mesh_terms=Time-to-Pregnancy&page=4#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Quels sont les symptômes de l'hépatite A ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, nausées, douleurs abdominales et jaunisse."
}
},
{
"@type": "Question",
"name": "L'hépatite B peut-elle être asymptomatique ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, de nombreuses personnes infectées par l'hépatite B ne présentent pas de symptômes."
}
},
{
"@type": "Question",
"name": "Comment se manifeste l'hépatite C ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent inclure fatigue, douleurs articulaires et jaunisse, mais souvent absents."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une hépatite aiguë ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent une forte fièvre, des douleurs abdominales et une urine foncée."
}
},
{
"@type": "Question",
"name": "L'hépatite virale peut-elle causer des complications ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications comme la cirrhose ou le cancer du foie peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment les vaccins contre l'hépatite A sont-ils administrés ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils sont généralement administrés par injection intramusculaire en deux doses."
}
},
{
"@type": "Question",
"name": "Qui devrait recevoir le vaccin contre l'hépatite B ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est recommandé pour tous les nourrissons, les enfants et les adultes à risque."
}
},
{
"@type": "Question",
"name": "Les vaccins contre l'hépatite A sont-ils efficaces ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils offrent une protection d'environ 95% après la vaccination complète."
}
},
{
"@type": "Question",
"name": "À quel âge doit-on vacciner les enfants contre l'hépatite B ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "La vaccination doit commencer à la naissance, avec des doses supplémentaires à 1 et 6 mois."
}
},
{
"@type": "Question",
"name": "Les voyageurs doivent-ils se faire vacciner contre l'hépatite A ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la vaccination est recommandée pour les voyageurs se rendant dans des zones à risque."
}
},
{
"@type": "Question",
"name": "Quel est le traitement de l'hépatite A ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de traitement spécifique ; le repos et l'hydratation sont recommandés."
}
},
{
"@type": "Question",
"name": "Comment traite-t-on l'hépatite B chronique ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antiviraux peuvent être prescrits pour contrôler l'infection et prévenir les complications."
}
},
{
"@type": "Question",
"name": "L'hépatite C est-elle curable ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des traitements antiviraux modernes peuvent guérir l'hépatite C dans la plupart des cas."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont utilisés pour l'hépatite B ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les médicaments comme le ténofovir et l'entécavir sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Y a-t-il un vaccin pour l'hépatite C ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de vaccin efficace contre l'hépatite C."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications de l'hépatite B ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent la cirrhose, le cancer du foie et l'insuffisance hépatique."
}
},
{
"@type": "Question",
"name": "L'hépatite A peut-elle causer des complications ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Rarement, mais des complications comme l'insuffisance hépatique peuvent survenir chez les personnes âgées."
}
},
{
"@type": "Question",
"name": "Quels risques sont associés à l'hépatite C ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'hépatite C peut entraîner des maladies hépatiques chroniques et des cancers du foie."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications de l'hépatite ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La vaccination, le dépistage régulier et un mode de vie sain aident à prévenir les complications."
}
},
{
"@type": "Question",
"name": "Les complications de l'hépatite peuvent-elles être réversibles ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications, comme la fibrose, peuvent être réversibles avec un traitement approprié."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour l'hépatite A ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent le voyage dans des zones à risque et la consommation d'eau contaminée."
}
},
{
"@type": "Question",
"name": "Qui est à risque d'hépatite B ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes ayant des rapports sexuels non protégés et les utilisateurs de drogues injectables sont à risque."
}
},
{
"@type": "Question",
"name": "L'hépatite C est-elle transmissible par le sang ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'hépatite C se transmet principalement par le sang, notamment via les transfusions."
}
},
{
"@type": "Question",
"name": "Les travailleurs de la santé sont-ils à risque d'hépatite ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils sont exposés à un risque accru d'infection par contact avec le sang."
}
},
{
"@type": "Question",
"name": "Les personnes atteintes de maladies chroniques sont-elles plus à risque ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent avoir un risque accru de complications liées à l'hépatite."
}
}
]
}
]
}
To study the association between maternal exposure to arsenic, cadmium, lead, manganese and mercury, time-to-pregnancy (TTP) and infertility....
Pregnancy-based retrospective TTP cohort study....
Hospitals and clinics from ten cities across Canada....
A total of 1784 pregnant women....
Concentrations of arsenic, cadmium, lead, manganese and mercury were measured in maternal whole blood during the first trimester of pregnancy as a proxy of preconception exposure. Discrete-time Cox pr...
TTP was self-reported as the number of months of unprotected intercourse to become pregnant. Infertility was defined as TTP longer than 12 months....
A total of 1784 women were eligible for the analysis. Mean ± SD maternal age and gestational age at interview were 32.2 ± 5.0 years, and 11.6 ± 1.6 weeks, respectively. Exposure to arsenic, cadmium, m...
Blood concentrations of metals at typical levels of exposure among Canadian pregnant women were not associated with TTP or infertility. Further studies are needed to assess the role of lead, if any, o...
On the outbreak of the global COVID-19 pandemic, high-risk and vulnerable groups in the population were at particular risk of severe disease progression. Pregnant women were one of these groups. The i...
The aim of this study was to determine the usefulness of placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) in predicting the time for pregnancy termination in pregnant wom...
Forty-four pregnant women diagnosed with PE (22 weeks 0 days to 33 weeks 6 days gestation) were included in this study. The levels of sFlt-1 and PlGF, and the sFlt-1/PlGF ratio were compared between t...
Among sFlt-1, PlGF, and sFlt-1/PlGF, sFlt-1 was the most significantly associated with the timing of pregnancy termination. sFlt-1 cutoff values of 8682.1 pg/ml (AUC 0.71; 95%Cl, 0.5191-0.9052) and 7,...
This study showed that sFlt-1 may be effective in predicting the timing of pregnancy termination. However, the number of cases was small and, thus, the results were not definitive. This finding should...
Worldwide, there is an alert due to the increase in the seroprevalence of hepatitis B virus (HBV). This can cause up to 3.5% of chronic diseases, of which 40% present secondary complications and/ or e...
To determine the seroprevalence of HBV in pregnant women at the time of delivery....
Observational, descriptive, cross-sectional study with cross-association between 2018 and 2019 at the Hospital Carlos Van Buren (HCVB), in Valparaiso, Chile. All pregnant women admitted for delivery c...
1,355 pregnant women were analyzed. 87.7% were Chilean, 5.5% Haitian, 4.2% Venezuelan, and 2.6% were of other nationalities. 0.3% were positive for HBV. The prevalence of HBV in Chileans was 0.08% and...
HBV seroprevalence in HCVB pregnant women was 0.3%, similar to that described in the general population in Chile. There was no coinfection with other sexually transmitted diseases. The only predictor ...
To evaluate associations between low job control (operationalized as job independence and freedom to make decisions) and time-to-pregnancy. Low job control, a form of workplace stress, is associated w...
We used data from Pregnancy Study Online (PRESTO), an internet-based preconception cohort study of couples trying to conceive in the U.S. and Canada. We estimated fecundability ratios (FRs) and 95% co...
Participants self-identified as female, were aged 21-45 years, and reported ≤6 cycles of pregnancy attempt time at enrollment (2018-2022)....
We assessed job control by matching participants' baseline self-reported occupation and industry with standardized occupation codes from the NIOSH Industry and Occupation Computerized Coding System, t...
Our main outcome measure was fecundability. Participants completed self-administered questionnaires at baseline and every 8 weeks for up to 12 months or until reported pregnancy, whichever occurred fi...
Among 3,110 participants, lower job independence was associated with reduced fecundability. Compared with the fourth (highest) quartile, corresponding to the most job independence, FRs (95% CI) for fi...
Lower job control, a work-related stressor, may adversely influence time-to-pregnancy. As job control is a condition of work (i.e., not modifiable by individuals), findings may strengthen arguments fo...
To investigate the efficacy and outcomes of chromosomal microarray (CMA) in the cytogenomic evaluation of products of conception (POC)....
Over a 42-month period, 323 POC samples were tested by CMA. Results were assessed using variables including phenotype, gestational age, results from orthogonal testing, and follow-up parental analysis...
CMA identified cytogenetic abnormalities in 47.4% of first trimester losses and 10.9% of second and third trimester losses. Chromosomal microarray results specifically from 5 to 7-week losses showed s...
Our findings of specific types of genetic abnormalities and the respective frequencies by gestational age closely align with those of published karyotype studies, supporting the use of routine CMA tes...
To estimate temporal trends of stroke in the peripartum period and to assess the relationship between stroke and maternal adverse outcomes vis-à-vis timing and hypertension....
We conducted a retrospective, cross-sectional study using the National Inpatient Sample to identify hospitalizations with pregnancy-associated stroke in the United States (2016-2019). Temporal trends ...
Among 15,977,644 pregnancy hospitalizations, 6,100 hospitalizations (38.2/100,000 hospitalizations) were with pregnancy-associated stroke. Of these, 3,635 (59.6%) had antepartum pregnancy-associated s...
A nationally representative sample of hospitalizations in the United States indicates an increasing trend in the rate of postpartum stroke. Almost half of hospitalizations with pregnancy-associated st...
As melanoma is common among young women, the impact of pregnancy on melanoma prognosis is of interest....
The purpose of this study was to examine the association between pregnancy and survival in female melanoma patients of childbearing age....
We performed a population-level, retrospective cohort study of women of childbearing age (18-45 years) diagnosed with melanoma from 2007 to 2017 using administrative data from Ontario, Canada. Patient...
Of 1312 women with melanoma, most did not experience pregnancy (84.1%), with 7.6% experiencing a pregnancy-associated melanoma and 8.2% experiencing a pregnancy after melanoma. Pregnancy before melano...
In this population-level analysis of female melanoma patients of childbearing age, pregnancy was not associated with a difference in survival, suggesting that pregnancy is not associated with a worse ...
To assess the association between the adoption of presumptive eligibility for pregnancy Medicaid in Kansas in 2016 and timely prenatal care access....
2012-2019 National Center for Health Statistics natality files....
We used difference-in-differences to compare outcomes before (2012-2015) and after (2017-2019) presumptive eligibility in Kansas relative to seven control group states overall and stratified by matern...
All live births among adults aged 20 or older in Kansas, Idaho, Missouri, Nebraska, Tennessee, Utah, Wisconsin, and Wyoming....
Among all births, we found no evidence that presumptive eligibility in Kansas resulted in changes in prenatal care use. Among individuals with high school education or less, presumptive eligibility wa...
Presumptive eligibility in Medicaid non-expansion states may lead to small improvements in early prenatal care among individuals with lower education, but other interventions may be needed....
Introduction Multiple pregnancy is an established risk factor for fetal death. This study aimed to examine the impact of multifetal pregnancies on stillbirth rates (SBRs) in the Greek population. Meth...
